CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 73 enrolled
Drug / intervention
Bilastine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02513290
NCT02513290Phase 4Completed
CompareCT.gov

Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine

Universidade do Sul de Santa Catarina·interventional·Posted Jul 31, 2015·Updated May 7, 2018

In Brief

A Phase 4 clinical trial evaluating Bilastine and Loratadine for Allergic Rhinitis. Completed, enrolled 73 participants.

Detailed Summary

The purpose of this study was to verify whether there were differences in health-related quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to those treated with loratadine 10 mg.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 31, 2015
Enrollment StartAug 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.9 years ago

Interventions

Bilastinedrug

Loratadinedrug